Relapsed or Refractory B-cell Malignancies research hub
9 indexed studies · 5 currently recruiting
- recruitingPHASE1
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
This study is testing a new medicine called EXS73565 for people with certain types of B-cell cancers that have come back or not responded to usual treatments. We want to find a safe dose and see how it works.
Georgia · Greece · Moldova - active not recruitingPHASE3
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
This study is looking at a new drug, epcoritamab, combined with standard treatments for follicular lymphoma, a type of blood cancer. We want to see if this combination is safe and effective in people who haven't been treated for this condition before.
United States · Australia · Belgium - recruitingPHASE2
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
This study is testing a new medicine called Surovatamig for adults with certain types of B-cell non-Hodgkin lymphoma that has returned or not responded to previous treatments. It aims to see how well it works and if it's safe.
United States · Australia · Brazil - recruitingPHASE1
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
This study is testing a new medicine, NX-5948, for adults with certain types of blood cancer that have come back or not responded well to previous treatments. It aims to find out if the medicine is safe and helps fight the cancer, starting with small doses and gradually increasing.
United States · France · Italy - active not recruitingPHASE3
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
This study looks at a new drug, epcoritamab, combined with standard medicines (R2) for adults with follicular lymphoma that has come back or not responded to previous treatments. It aims to see how safe and effective this new combination is.
United States · Argentina · Australia - not yet recruiting
The Microbiome in Blood Cancer and HLH
This study looks at how gut bacteria and viruses, called the microbiome, affect people with certain blood cancers and a severe inflammatory condition called HLH. Researchers want to better understand how these tiny organisms influence treatment response and side effects, aiming to improve future care.
United Kingdom - recruitingPHASE3
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
This study is testing a new drug, odronextamab, for adults with follicular lymphoma that hasn't been treated before. It aims to find out if the drug is safe and how well it works compared to current standard treatments.
United States · Australia · Austria - active not recruitingPHASE3
A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma
This study compares a new cell therapy, called tisagenlecleucel, with standard treatments for adults with follicular lymphoma that has come back or not responded to previous therapies. We want to see if the new therapy can keep the lymphoma under control for longer.
Australia · Austria · Canada - active not recruitingPHASE3
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
This study is testing a new drug called odronextamab with chemotherapy for follicular lymphoma. It compares this new combination to the usual treatment (rituximab with chemotherapy) to see if it's safe, works well, and helps people with this type of cancer.
United States · Australia · Austria